Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s13256-020-02503-9 http://scihub22266oqcxt.onion/10.1186/s13256-020-02503-9 33054818!7556888!33054818     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Case+Rep 2020 ; 14 (1): 187 Nephropedia Template TP {{tp|p=33054818|t=2020. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report |pdf=|usr=}}{{33054818}} gab.com Text Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report JO: J Med Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=33054818 #FOAvip BACKGROUND: The understanding of coronavirus disease 2019 (COVID-19) is rapidly evolving. Although it is primarily a respiratory illness, other manifestations, such as Guillain-Barre syndrome, immune thrombocytopenia, and immune-mediated thrombotic thrombocytopenic purpura, have been described. We present a case of a patient with hemophagocytic lymphohistiocytosis secondary to COVID-19 treated with tocilizumab with a marked biochemical improvement. CASE PRESENTATION: In this case report we present a Caucasian patient with COVID-19 who developed a marked elevation of inflammatory parameters with ferritin 36,023 mug/L, but also elevated C-reactive protein 334 mg/L and lactate dehydrogenase 1074 U/L, 1 week after admission to the intensive care unit. He met five of eight criteria for hemophagocytic lymphohistiocytosis, but he lacked the high fever and cytopenia seen in the majority of cases. He was treated with tocilizumab, a monoclonal antibody targeting the interleukin-6 receptor, and over the next days, a rapid decrease in ferritin and C-reactive protein levels was observed. However, his respiratory failure only improved gradually, and he was weaned off the respirator 11 days later. CONCLUSION: COVID-19 may induce a hyperinflammatory clinical picture and in some cases develop into hemophagocytic lymphohistiocytosis. In our patient's case, therapeutic interleukin-6 blockade abrogated signs of hyperinflammation but did not seem to improve pulmonary function. Measurement of ferritin and C-reactive protein, as well as quantification of interleukin-6 on indication, should be performed in patients with severe COVID-19. Specific treatment in such patients must also be contemplated, preferably in randomized controlled trials. Twit Text FOAVip Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report ????J Med Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=33054818 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33054818 #FOAvip English Wikipedia <ref>{{Cite pmid|33054818}}</ref> Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report #MMPMID33054818 Tholin B; Hauge MT; Aukrust P; Fehrle L; Tvedt TH J Med Case Rep 2020[Oct]; 14 (1): 187 PMID33054818show ga BACKGROUND: The understanding of coronavirus disease 2019 (COVID-19) is rapidly evolving. Although it is primarily a respiratory illness, other manifestations, such as Guillain-Barre syndrome, immune thrombocytopenia, and immune-mediated thrombotic thrombocytopenic purpura, have been described. We present a case of a patient with hemophagocytic lymphohistiocytosis secondary to COVID-19 treated with tocilizumab with a marked biochemical improvement. CASE PRESENTATION: In this case report we present a Caucasian patient with COVID-19 who developed a marked elevation of inflammatory parameters with ferritin 36,023 mug/L, but also elevated C-reactive protein 334 mg/L and lactate dehydrogenase 1074 U/L, 1 week after admission to the intensive care unit. He met five of eight criteria for hemophagocytic lymphohistiocytosis, but he lacked the high fever and cytopenia seen in the majority of cases. He was treated with tocilizumab, a monoclonal antibody targeting the interleukin-6 receptor, and over the next days, a rapid decrease in ferritin and C-reactive protein levels was observed. However, his respiratory failure only improved gradually, and he was weaned off the respirator 11 days later. CONCLUSION: COVID-19 may induce a hyperinflammatory clinical picture and in some cases develop into hemophagocytic lymphohistiocytosis. In our patient's case, therapeutic interleukin-6 blockade abrogated signs of hyperinflammation but did not seem to improve pulmonary function. Measurement of ferritin and C-reactive protein, as well as quantification of interleukin-6 on indication, should be performed in patients with severe COVID-19. Specific treatment in such patients must also be contemplated, preferably in randomized controlled trials. |*Coronavirus Infections/blood/complications/diagnosis/therapy[MESH] |*Interleukin-6/analysis/antagonists & inhibitors[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/blood/complications/diagnosis/therapy[MESH] |Aged[MESH] |Antibodies, Monoclonal, Humanized/*administration & dosage[MESH] |Antibodies, Monoclonal/administration & dosage[MESH] |Betacoronavirus/*isolation & purification[MESH] |C-Reactive Protein/analysis[MESH] |COVID-19[MESH] |Ferritins/blood[MESH] |Humans[MESH] |Inflammation/*blood[MESH] |Lymphohistiocytosis, Hemophagocytic/etiology[MESH] |Male[MESH] |Respiration, Artificial/methods[MESH] |SARS-CoV-2[MESH]Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated (epmc).pdf DeepDyve Pubget Overpricing